Background：Cardiovascular diseases dominated by atherosclerotic cardiovascular disease (ASCVD) are the leading cause of death among residents in urban and rural China. Low - density lipoprotein cholesterol (LDL - C) is a pathogenic risk factor for ASCVD. With the continuous increase in the disease burden of ASCVD in China and the breakthrough progress in global lipid research, the revision of the lipid guideline in China is imperative.
Core Target：LDL - C is still recommended as the primary target for lipid intervention, and its target value is determined based on risk stratification.
Treatment Strategy：On the basis of lifestyle intervention, moderate - intensity statins are recommended as the initial drug therapy. When necessary, a target - achieving strategy of combining cholesterol absorption inhibitors and/or proprotein convertase subtilisin kexin 9 inhibitors is adopted.
Coverage Scope：It covers lipid management throughout the whole life cycle from children to the elderly, aiming to improve the level of lipid management in China and promote the prevention and treatment of ASCVD.
英文版本获取渠道
MedSci 梅斯医学：可通过该链接直接查看指南英文内容，页面清晰呈现指南核心信息及相关关联内容。
PubMed：检索文献标题 “Chinese guidelines for lipid management (2023)”，即可找到该指南相关英文收录内容，其标注的发表相关信息为 “Joint Committee on the Chinese Guidelines for Lipid Management. Zhonghua Xin Xue Guan Bing Za Zhi. 2023”。